Form 4 for VNRX VOLITIONRX LTD
Accepted 2024-12-10 00:00:00 ET · period of report 2024-12-09 · accession 0001477932-24-007969 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-10 | 2024-12-09 | VNRX | Reynolds Cameron John | Pres, CEO, Dir | P - Purchase | $0.57 | +139.8K | 2.12M | +7% | +$79.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-09 | P | A | 139,811 | $0.57 | 2,117,404 | D | — | — | (F1) Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx. |